Tag

Vaccine Trial

All articles tagged with #vaccine trial

health2 months ago•3 min saved

DR Congo Launches Trial for Ervebo Vaccine Against Rare Bundibugyo Ebola Strain

The Democratic Republic of the Congo (DRC) is beginning a clinical trial to test the Ervebo vaccine against the Bundibugyo strain of Ebola, which is causing the country's deadliest outbreak. The World Health Organization (WHO) allocated 70,000 doses, with 20,000 reserved for the trial and 50,000 for frontline health workers. While Ervebo is proven effective against the Zaire strain, its efficacy against Bundibugyo is unknown. The outbreak, declared in May 2026, has killed nearly 2,500 people and is spreading faster than the response can manage. Gavi is funding the shipment with $7 million, while the M23 rebel group has imposed travel restrictions in the east to curb transmission.

via BBC|

#bundibugyo #dr-congo #ebola

health2 months ago•2 min saved

DRC Ebola Outbreak Surges to Record Pace, Death Toll Tops 2,000

DRC's Ebola outbreak has killed more than 2,000 people and infected 4,381 across five provinces—the fastest-growing outbreak in the country and the second-largest globally since 2014–16 West Africa—with response hampered by unpaid health workers, misinformation and traditional burials; there is no approved treatment or vaccine for the Bundibugyo strain yet, though vaccine trials are under way with results months away; the outbreak began in February and was declared in May, and a potential Ebola case in Israel linked to a traveler from the DRC is under investigation.

via Al Jazeera|

#drc #ebola #health

world9 months ago•5 min saved

Guinea-Bissau halts US-backed hepatitis B vaccine trial amid ethical and sovereignty concerns

Guinea-Bissau suspended a US-funded, Denmark-led hepatitis B vaccine trial after ethics-review gaps and concerns about consent, with the health ministry citing sovereignty as the deciding factor. The Africa CDC will review the protocol alongside invited US and Danish officials, amid criticism from some experts and a political shift following a coup. The trial design—with 7,000 infants vaccinated at birth and 7,000 withheld for comparison—raised ethical alarms, contrasting with WHO guidance that recommends newborn vaccination within 24 hours and Guinea-Bissau’s current six-week schedule; the outcome will hinge on the ministry’s decision.

via The Guardian|

#africa-cdc #ethics #guinea-bissau

world9 months ago•13 min saved

Guinea-Bissau pauses hepatitis B vaccine trial for ethics review

Guinea-Bissau has paused a hepatitis B vaccine study linked to supporters of former President Donald Trump to undergo an ethics review, delaying the trial as regulators assess safety and informed consent.

via AP News|

#ethics-review #guinea-bissau #hepatitis-b

world9 months ago•3 min saved

HHS Faces Backlash Over Controversial Guinea-Bissau Vaccine Trial and Africa CDC Clash

The article reports that a U.S. HHS-funded hepatitis B vaccine trial in Guinea-Bissau—budgeted at $1.6 million and enrolling 14,000 infants, with only half receiving the vaccine—has sparked ethics concerns and comparisons to the Tuskegee study; Africa CDC says the trial is not affiliated with the US CDC and claims it has been halted, while HHS asserts the study will proceed; the affair unfolds amid a broader WHO-Africa CDC collaboration and an anticipated press conference, keeping the situation in flux.

via Futurism|

#africa-cdc #ethics #guinea-bissau

health2 years ago•2 min saved

"Jacksonville Seeks Volunteers for New COVID-19 Vaccine Trial"

The Jacksonville Center for Clinical Research is seeking participants for Phase 2 trials of a new oral COVID-19 vaccine developed by Vaxart. The pill-based vaccine, which is room-temperature stable, aims to reduce viral shedding and is being tested for effectiveness against the FLirt-variant of Omicron. The trial will last one year, and interested individuals can contact the center to participate.

via WJXT News4JAX |

#covid-19 #health #jacksonville

health2 years ago•2 min saved

"UC Launches Groundbreaking Pancreatic Cancer Vaccine Trial"

The University of Cincinnati Cancer Center is conducting a Phase 2 clinical trial for a personalized vaccine to treat pancreatic cancer, utilizing mRNA technology similar to that used for COVID-19 vaccines. After surgery, a personalized vaccine is developed and administered to patients, followed by standard chemotherapy and booster shots. The trial aims to enroll 260 patients globally, with minimal side effects reported in Phase 1 and promising results, including an 25% cure rate. Researchers believe this vaccine could be a game changer in pancreatic cancer treatment.

via WCPO 9 Cincinnati|

#health #mrna-technology #pancreatic-cancer

health2 years ago•12 min saved

"University of Cincinnati Cancer Center seeks patients for pancreatic cancer vaccine trial"

The University of Cincinnati Cancer Center has initiated enrollment for a Phase 2 clinical trial testing a vaccine for pancreatic cancer, utilizing mRNA technology similar to that used in COVID-19 vaccines. The trial aims to enroll 260 patients globally and offers a personalized vaccine targeting each individual's cancer specifically. Patients receive injections of the vaccine after surgery and chemotherapy, with minimal reported side effects. The trial has shown promising results, with 25% of patients in the Phase 1 trial being completely cured of their cancer. For more information on the trial, individuals can call 513-584-7698 or email [email protected].

via WLWT Cincinnati|

#clinical-trial #health #mrna-technology

health2 years ago•5 min saved

"Fast-Tracking Breast Cancer Vaccines: Hope for Patients in Clinical Trials"

NBC News correspondent Kristen Dahlgren left journalism to launch the Pink Eraser Project, aiming to accelerate the development of a breast cancer vaccine. Dr. Nora Disis' vaccine trial at the University of Washington's Cancer Vaccine Institute has shown promising results, with breast cancer survivor Jennifer Brouwer participating in the Phase 2 trial. The vaccine aims to teach the body to identify and destroy cancer stem cells using the immune system. The Pink Eraser Project seeks to streamline effective studies and bring together leading researchers to eradicate breast cancer as a fatal disease. Brouwer, hopeful for a medical breakthrough, encourages women to consider participating in clinical trials and not to dismiss the idea due to misconceptions.

via WOODTV.com|

#breast-cancer #clinical-trials #health

health2 years ago•2 min saved

"Human Trials Begin for Groundbreaking Nipah Virus Vaccine"

The University of Oxford has initiated the first human trial for a vaccine against the Nipah virus, a zoonotic pathogen with a mortality rate of up to 75%. The ChAdOx1 NipahB vaccine is being tested on 51 volunteers to evaluate its safety and immune responses. With no approved vaccines or treatments for Nipah virus, this trial marks a significant step in pandemic preparedness, and further research is expected to follow in Nipah virus-affected countries.

via Euronews|

#health #infectious-diseases #nipah-virus

health2 years ago•2 min saved

HIV Vaccine Trial in Africa Ends in Disappointment

The PrEPVacc HIV vaccine trial, considered the "last roll of the dice" in the search for an effective HIV vaccine, has been halted due to disappointing results. The trial, led by African researchers with support from European scientists, was testing two experimental vaccines alongside a new form of oral pre-exposure prophylaxis (PrEP). While there are no safety concerns, the vaccine component was found to be ineffective in preventing HIV. This setback is a significant blow to the medical community, which has been searching for an HIV vaccine for 36 years. The trial's failure highlights the urgent need for new vaccine approaches and technology.

via CNN|

#health #hiv #hiv-prevention

health2 years ago•2 min saved

HIV Vaccine Trial in Africa Ends in Disappointment

The first trial in Africa testing two combination vaccines to prevent HIV has been halted after researchers determined that the vaccines were not effective in reducing the risk of acquiring HIV. The trial, which involved 1,500 participants in Uganda, Tanzania, and South Africa, was stopped after an interim review of progress. The final results are expected to be released in late 2024. This setback means that there are currently no HIV vaccines being tested for efficacy anywhere in the world. Despite the disappointing results, researchers remain optimistic about the development of an effective HIV vaccine in the future.

via The Guardian|

#africa #disappointing-results #health

health3 years ago•1 min saved

"Promising Results: Pfizer and BioNTech's Combined COVID-Flu Vaccine Shows Strong Immune Response"

Pfizer and BioNTech have announced that their flu-COVID vaccine has generated a strong immune response against strains of both viruses in an early- to mid-stage trial. The companies plan to proceed with a late-stage trial in the coming months. The vaccine has the potential to simplify immunization practices by addressing two respiratory diseases with a single injection. The trial data showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.

via KSL.com|

#biontech #flu-covid-shot #health

health3 years ago•0 min saved

"Promising Results: Pfizer and BioNTech's Flu-COVID Shot Elicits Robust Immune Response in Trial"

Pfizer and BioNTech announced that their flu-COVID vaccine generated a strong immune response against strains of both viruses in an early- to mid-stage trial. The vaccine candidates were compared to a licensed influenza vaccine and the companies' updated COVID-19 vaccine, and the data showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. The companies plan to proceed with a late-stage trial in the coming months, with the potential to simplify immunization practices by addressing two respiratory diseases with a single injection.

via Reuters|

#biontech #flu-covid-shot #health

health3 years ago•2 min saved

"Vermont renews Lyme disease vaccine trial"

The University of Vermont Medical Center and UVM's Larner College of Medicine are recruiting participants for a clinical trial of a Pfizer vaccine to protect against Lyme disease. The trial, called VALOR, will take place over 30 months and involve at least seven clinic visits and several blood draws. Lyme disease, caused by tick-borne bacteria, is increasingly present in Vermont, with over half of all ticks collected in the state in 2020 found to be infected. Currently, there are no approved vaccines for Lyme disease in humans, but Pfizer's Phase 2 trial showed promising results, and the Phase 3 trial aims to determine the vaccine's effectiveness.

via VTDigger|

#health #lyme-disease #pfizer